[Erythropoietin and radiotherapy].
Erythropoietin (EPO) is a glycoprotein hormone. This hormone is a growth factor for red blood cells precursors in the bone marrow. The decrease of oxygen partial pressure, a reduced number of erythrocytes caused by bleeding or excessive destruction, or increased tissues oxygen requirements lead to increased secretion of EPO. Its action takes place on bone marrow erythroblastic cells through specific receptors. EPO stimulates the proliferation of red cell precursors stem cells in the bone marrow, thus increasing their production in one to two weeks. The effectiveness of EPO at increasing haemoglobin and improving patients' quality of life has been demonstrated by several studies. However, its use in radiotherapy remains controversial. While tumour hypoxia caused by anaemia is a factor of radio resistance and thus a source of local failure, tumour expression of EPO receptors presents a significant risk for tumour progression and neo-angiogenesis, which would be increased during the administration of EPO. The purpose of this article is to answer the question: is there a place for EPO in combination with radiotherapy in the management of cancer?
Le Fur
E
E
Département de radiothérapie, CHU de Morvan, Brest, France.
Albarghach
M-N
MN
Pradier
O
O
D000740:Anemia / Q000188:drug therapy; D014408:Biomarkers, Tumor / Q000378:metabolism; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D017467:Receptors, Erythropoietin / Q000378:metabolism*; D011994:Recombinant Proteins
D014408:Biomarkers, Tumor; D017467:Receptors, Erythropoietin; D011994:Recombinant Proteins; D004921:Erythropoietin